<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144843</url>
  </required_header>
  <id_info>
    <org_study_id>Apatinib_GC</org_study_id>
    <nct_id>NCT03144843</nct_id>
  </id_info>
  <brief_title>Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.</brief_title>
  <official_title>A Phase II Multicenter, Randomized, Double-blind Study of Apatinib Combined With Paclitaxol Versus Placebo With Paclitaxol as Second Line Therapy for Advanced Gastric / Esophagogastric Junction Adenocarcinoma With Peritoneal Metastasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, randomized, double-blind study will evaluate the efficacy and safety of
      apatinib combined with paclitaxol versus placebo combined with paclitaxol in advanced gastric
      cancer or gastroesophageal junction carcinoma patients with peritoneal metastasis.

      Patients will be randomized to one treatment arm: Arm A: apatinib 500mg qd, Paclitaxol
      80mg/m2, d1, d8, d15,every 4 weeks ; Arm B: placebo 500mg qd, Paclitaxol 80mg/m2, d1, d8,
      d15,every 4 weeks ; Tumor assessment will be done every 8 weeks according to RECIST 1.1. The
      primary endpoint is progression free survival (PFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is the second most common cause of cancer‑related deaths worldwide, and most
      patients are diagnozed at advanced stage in China. Peritoneal metastasis is the most common
      metastatic site. For gastric cancer patients with peritoneal metastasis, chemotherapy can
      bring survival benefit versus best sportive care. Paclitaxol is the standard second line
      chemotherapy for advanced gastric cancer patients.

      Apatinib mesylate is a small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2)
      tyrosine kinase inhibitor (TKI). It has been approved as third-line treatment for patients
      with advanced gastric adenocarcinoma in China.

      This multicenter, randomized, double-blind study will evaluate the efficacy and safety of
      apatinib combined with paclitaxol versus placebo combined with paclitaxol in advanced gastric
      cancer or gastroesophageal junction carcinoma patients with peritoneal metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenters ramdomized double-blind phase II study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>The time from randomize to progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>The time from randomize to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>The rate of complete response and partial response according to RECIST guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>The rate of complete response , partial response and stable disease according to RECIST guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (incidence of adverse events) [</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Incidence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Paclitaxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Paclitaxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients, aged between 18 and 75 years old;

          2. Histologically confirmed advanced or metastatic adenocarcinoma of gastric cancer(AGC)
             , including adenocarcinoma of the gastroesophageal junction ;

          3. At least one measurable and evaluable disease based on response evaluation criteria in
             solid tumors (RECIST v1.1); and confirmed as peritoneal metastasis by CT scan or
             laparoscope

          4. Patients must have received one prior chemotherapy regimen for AGC;First-line therapy
             must have included a combination of at least a platinum-based treatment given
             concurrently, and must have experienced disease progression during or after first-line
             therapy for their disease;

          5. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;

          6. Life expectancy of more than 3 months;

          7. Duration from the last therapy is more than 6 weeks for nitroso or mitomycin, More
             than 4 weeks for other cytotoxic agents, operation or radiotherapy;

          8. Adequate hepatic, renal, heart, and hematologic functions ( hemoglobin≥ 90g/L,
             platelets ≥ 80 × 10*9/L, neutrophil ≥1.5 × 10*9/L, serum creatinine≤ 1.5mg/dl, total
             bilirubin ≤1.5 ×ULN, and serum transaminase≤2.5×ULN)

        Exclusion Criteria:

          1. Pregnant or lactating women;

          2. History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             insitu of uterine cervix;

          3. Prior chemotherapy regimen have included taxane (docetaxel or paclitaxel); 4.
             Uncontrolled hypertension;

        5. Intercurrence with one of the following: coronary artery disease, arrhythmia and heart
        failure; 6. Urine protein&gt;grade 1; 7. Any factors that influence the usage of oral
        administration; 8. Patients with a clear tendency of gastrointestinal bleeding; 9. Abnormal
        coagulation function(INR≥1.5, APTT≥1.5 ULN); 10. Abuse of alcohol or drugs; 11. Less than 4
        weeks from the last clinical trial; 12. Prior treatment with antivascular endothelial
        growth factor or the other anti angiogenesis therapy; 13. Evidence of central nervous
        system(CNS) metastasis; 14. Disability of serious uncontrolled intercurrence infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Foshan people's Hospital</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang</last_name>
      <phone>075783161035</phone>
      <email>m18038863618@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer center of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fenghua Wang, MD, PhD</last_name>
      <phone>86-020-87342490</phone>
      <email>wangfh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Miao-Zhen Qiu, MD, PhD</last_name>
      <phone>86-020-87342490</phone>
      <email>qiumzh@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Rui-Hua Xu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Fenghua Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Peritoneal metastasis</keyword>
  <keyword>Paclitaxol</keyword>
  <keyword>Apatinib</keyword>
  <keyword>Second-line chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

